ReviewSignal transduction and targeted therapy2026
Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As a key regulator of the immune system, regulatory T cells (Treg cells) suppress excessive immune responses and maintain self-tolerance through various immunosuppressive mechanisms, both contact-dependent and contact-independent. They have demonstrated significant therapeutic potential in immune-related diseases and some non-immune diseases. In this paper, we systematically review the induction strategies of Treg cells, covering various aspects including antigenic stimulation, cytokine modulation, metabolic pathways, epigenetic regulation, drug induction, and engineered technology. Although each strategy has its own advantages, no single approach can comprehensively address the complex issues surrounding Treg cell stability, target specificity, and large-scale production. Therefore, we propose that integrating multiple induction strategies during the Treg cell induction process is crucial for designing Treg cell therapies with superior functionality and broader applications, thereby overcoming the current limitations of Treg cell therapies. In addition, we introduce their therapeutic applications in immune diseases (such as autoimmune disease, organ transplantation, allergic asthma, and cancer) and non-immune diseases (such as insulin resistance, tissue repair, fibrotic diseases, and osteoporosis), and recent advancements. We also discuss current research bottlenecks of Treg cell-based therapeutic strategies and provide an outlook on their future development, aiming to deepen the understanding of Treg cells and promote the advancement of Treg cell-based cellular therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.